Ticker
ADMA

Price
3.85
Stock movement down
-0.11 (-2.78%)
Company name
ADMA Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
850.48M
Ent value
960.44M
Price/Sales
3.92
Price/Book
5.60
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
35.00
PEG
-
EPS growth
-
1 year return
21.84%
3 year return
28.37%
5 year return
-5.47%
10 year return
-
Last updated: 2023-11-27
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 16, 2023

iO Charts is a Seeking Alpha partner

ADMA Biologics, Inc. is undervalued based on long-term potential and now is free cash flow positive. Read more about ADMA stock here.
November 9, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADMA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.92
Price to Book5.60
EV to Sales4.42
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Head, Business...
November 9, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 8, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count220.90M
EPS (TTM)-0.53
FCF per share (TTM)-0.60

Income statement

Loading...
Income statement data
Revenue (TTM)217.09M
Gross profit (TTM)46.70M
Operating income (TTM)-63.35M
Net income (TTM)-104.68M
EPS (TTM)-0.53
EPS (1y forward)0.11

Margins

Loading...
Margins data
Gross margin (TTM)21.51%
Operating margin (TTM)-29.18%
Profit margin (TTM)-48.22%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash86.52M
Net receivables15.51M
Total current assets270.40M
Goodwill3.53M
Intangible assets1.01M
Property, plant and equipment58.26M
Total assets348.46M
Accounts payable13.23M
Short/Current long term debt154.44M
Total current liabilities39.27M
Total liabilities196.49M
Shareholder's equity151.97M
Net tangible assets151.97M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-98.35M
Capital expenditures (TTM)20.69M
Free cash flow (TTM)-119.05M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-68.88%
Return on Assets-30.04%
Return on Invested Capital-68.47%
Cash Return on Invested Capital-77.87%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.95
Daily high3.95
Daily low3.82
Daily Volume1.25M
All-time high12.49
1y analyst estimate5.13
Beta0.87
EPS (TTM)-0.53
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADMAS&P500
Current price drop from All-time high-69.18%-4.86%
Highest price drop-91.27%-56.47%
Date of highest drop11 Oct 20219 Mar 2009
Avg drop from high-59.30%-11.47%
Avg time to new high104 days13 days
Max time to new high2263 days1805 days
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
November 7, 2023

iO Charts is a Seeking Alpha partner

ADMA Biologics, specializes in plasma-derived biologics, had 77% Q2 2023 revenue increase. Read more about ADMA stock here.
August 26, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADMA (ADMA Biologics Inc) company logo
Marketcap
850.48M
Marketcap category
Small-cap
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Employees
0
Investor relations
-
SEC filings
CEO
Adam S. Grossman
Country
USA
City
Ramsey
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director,...
August 10, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
August 9, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
August 8, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
July 19, 2023
There are fundamental, sentimental and valuation facts to suggest ADMA is mispriced in my opinion. ADMA stock is rated as a buy. Explore more here.
June 16, 2023
Today, we take a deeper look at ADMA Biologics, whose stock has doubled over the past year thanks to robust sales growth. Click for more on ADMA stock.
June 15, 2023
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director,...
May 11, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 10, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 9, 2023
Get the latest news and real-time alerts from ADMA Biologics, Inc. (ADMA) stock at Seeking Alpha.
May 2, 2023
ADMA Biologics recently reported their Q4 and Full-Year 2022 earnings, which revealed a beat on EPS and revenue. Check out my updated game plan for ADMA stock.
March 29, 2023
ADMA Biologics, Inc. (NASDAQ:NASDAQ:ADMA) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ETCompany ParticipantsSkyler Bloom - Senior Director of...
March 24, 2023
iO Charts is a Seeking Alpha partnerNext page